Inhibition of 5-lipoxygenase selectively triggers disruption of c-Myc signaling in prostate cancer cells

Journal of Biological Chemistry

Volumn 290, Issue 8, 2015, Pages 4994-5006

  Sarveswaran, Sivalokanathan ^a   Chakraborty, Debrup ^a   Chitale, Dhananjay ^b   Sears, Rosalie ^c   Ghosh, Jagadananda ^a,b,c  

^a HENRY FORD HOSPITAL   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES;

PROSTATE CANCER CELLS;

CELL SIGNALING;

ARACHIDONATE 5 LIPOXYGENASE; MESSENGER RNA; MYC PROTEIN; PROTEASOME; QUIFLAPON; STAT3 PROTEIN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; INDOLE DERIVATIVE; LIPOXYGENASE INHIBITOR; MYC PROTEIN, HUMAN; QUINOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; ENZYME DEGRADATION; ENZYME INHIBITION; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS; APOPTOSIS; ARACHIDONATE 5-LIPOXYGENASE; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; LIPOXYGENASE INHIBITORS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; QUINOLINES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84929465756     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.599035     Document Type: Article

References (66)

1. Meyer, N., and Penn, L. Z. (2008) Reflecting on 25 years with MYC. Nat. Rev. Cancer 8, 976-990
2. Ponzielli, R., Katz, S., Barsyte-Lovejoy, D., and Penn, L. Z. (2005) Cancer therapeutics: targeting the dark side of Myc. Eur. J. Cancer 41, 2485-2501
3. Wang, Y. H., Liu, S., Zhang, G., Zhou, C. Q., Zhu, H. X., Zhou, X. B., Quan, L. P., Bai, J. F., and Xu, N. Z. (2005) Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res. 7, R220-R228
4. Soucek, L., Whitfield, J., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., and Evan, G. I. (2008) Modelling Myc inhibition as a cancer therapy. Nature 455, 679-683
5. Kimura, S., Maekawa, T., Hirakawa, K., Murakami, A., and Abe, T. (1995) Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res. 55, 1379-1384
6. Holt, J. T., Redner, R. L., and Nienhuis, A. W. (1988) An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol. Cell. Biol. 8, 963-973
7. Iversen, P. L., Arora, V., Acker, A. J., Mason, D. H., and Devi, G. R. (2003) Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a phase I safety study in humans. Clin. Cancer Res. 9, 2510-2519
8. Siegel, R., Ward, E., Brawley, O., and Jemal, A. (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61, 212-236
9. Fleshner, N., Bagnell, P. S., Klotz, L., and Venkateswaran, V. (2004) Dietary fat and prostate cancer. J. Urol. 171, S19-S24
10. Kolonel, L. N., Nomura, A. M., and Cooney, R. V. (1999) Dietary fat and prostate cancer: Current status. J. Natl. Cancer Inst. 91, 414-428
11. Wang, Y., Corr, J. G., Thaler, H. T., Tao, Y., Fair, W. R., and Heston, W. D. (1995) Decreased growth of established prostate LNCaP tumors in nude mice fed a low-fat diet. J. Natl. Cancer Inst. 87, 1456-1462
12. Wang, D., and Dubois, R. N. (2010) Eicosanoids and cancer. Nat. Rev. Cancer 10, 181-193
13. Nie, D. (2007) Cyclooxygenases and lipoxygenases in prostate and breast cancers. Front. Biosci. 12, 1574-1585
14. Ghosh, J., and Myers, C. E. (1997) Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem. Biophys. Res. Commun. 235, 418-423
15. Anderson, K. M., Seed, T., Vos, M., Mulshine, J., Meng, J., Alrefai, W., Ou, D., and Harris, J. E. (1998) 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate 37, 161-173
16. Ghosh, J., and Myers, C. E. (1998) Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95, 13182-13187
17. Ghosh, J., and Myers, C. E. (1999) Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells. Adv. Exp. Med. Biol. 469, 577-582
18. Sarveswaran, S., Myers, C. E., and Ghosh, J. (2010) MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase. Cancer Lett. 291, 167-176
19. Sarveswaran, S., Thamilselvan, V., Brodie, C., and Ghosh, J. (2011) Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via downregulation of protein kinase C-epslilon. Biochim. Biophys. Acta 1813, 2108-2117
20. Sarveswaran, S., and Ghosh, J. (2013) OXER1, a G protein-coupled oxoeicosatetraenoid receptor, mediates the survival-promoting effects of arachidonate 5-lipoxygenase in prostate cancer cells. Cancer Lett. 336, 185-195
21. Ford-Hutchinson, A. W., Gresser, M., and Young, R. N. (1994) 5-Lipoxygenase. Annu. Rev. Biochem. 63, 383-417
22. Rådmark, O., Werz, O., Steinhilber, D., and Samuelsson, B. (2007) 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem. Sci. 32, 332-341
23. Rådmark, O., and Samuelsson, B. (2009) 5-Lipoxygenase: mechanisms of regulation. J. Lipid Res. 50, S40-S45
24. Rådmark, O., and Samuelsson, B. (2010) Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. Biochem. Biophys. Res. Commun. 396, 105-110
25. Brideau, C., Chan, C., Charleson, S., Denis, D., Evans, J. F., Ford-Hutchinson, A. W., Fortin, R., Gillard, J. W., Guay, J., Guévremont, D., Hutchinson, J. H., Jones, T. R., Leger, S., Mancini, J. A., McFarlane, C. S., Pickett, C., Piechuta, H., Prasit, P., Riendeau, D., Rouzer, C. A., Tagari, P., Vickers, P. J., Young, R. N., Abraham, W. M. (1992) Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. 70, 799-807
26. Prasit, P., Belley, M., Blouin, M., Brideau, C., Chan, C., Charleson, S., Evans, J. F., Frenette, R., Gauthier, J. Y., and Guay, J. (1993) A new class of leukotriene biosynthesis inhibitor: the development of MK-0591. J. Lipid Mediat. 6, 239-244
27. Ferguson, A. D., McKeever, B. M., Xu, S., Wisniewski, D., Miller, D. K., Yamin, T. T., Spencer, R. H., Chu, L., Ujjainwalla, F., Cunningham, B. R., Evans, J. F., and Becker, J. W. (2007) Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 317, 510-512
28. Evans, J. F., Ferguson, A. D., Mosley, R. T., and Hutchinson, J. H. (2008) What's all the FLAP about? 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol. Sci. 29, 72-78
29. Sampson, A. P. (2009) FLAP inhibitors for the treatment of inflammatory diseases. Curr. Opin. Investig. Drugs 10, 1163-1172
30. Adhikary, S., and Eilers, M. (2005) Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 6, 635-645
31. Gil, J., Kerai, P., Lleonart, M., Bernard, D., Cigudosa, J. C., Peters, G., Carnero, A., and Beach, D. (2005) Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res. 65, 2179-2185
32. Rohan, J. N., and Weigel, N. L. (2009) 1α,25-Dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology 150, 2046-2054
33. Dang, C. V. (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 19, 1-11
34. Dang, C. V., O'Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C., and Li, F. (2006) The c-Myc target gene network. Semin. Cancer Biol. 16, 253-264
35. Sears, R. C. (2004) The life cycle of c-myc: from synthesis to degradation. Cell Cycle 3, 1133-1137
36. Vervoorts, J., Lüscher-Firzlaff, J., and Lüscher, B. (2006) The ins and outs of MYC regulation by posttranslational mechanisms. J. Biol. Chem. 281, 34725-34729
37. Welcker, M., Orian, A., Jin, J., Grim, J. E., Grim, J. A., Harper, J. W., Eisenman, R. N., and Clurman, B. E. (2004) The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl. Acad. Sci. U.S.A. 101, 9085-9090
38. Wolfer, A., and Ramaswamy, S. (2011) MYC and metastasis. Cancer Res. 71, 2034-2037
39. Wolfer, A., Wittner, B. S., Irimia, D., Flavin, R. J., Lupien, M., Gunawardane, R. N., Meyer, C. A., Lightcap, E. S., Tamayo, P., Mesirov, J. P., Liu, X. S., Shioda, T., Toner, M., Loda, M., Brown, M., Brugge, J. S., and Ramaswamy, S. (2010) MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc. Natl. Acad. Sci. U.S.A. 107, 3698-3703
40. Ma, L., Young, J., Prabhala, H., Pan, E., Mestdagh, P., Muth, D., Teruya-Feldstein, J., Reinhardt, F., Onder, T. T., Valastyan, S., Westermann, F., Speleman, F., Vandesompele, J., and Weinberg, R. A. (2010) miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12, 247-256
41. Rapp, U. R., Korn, C., Ceteci, F., Karreman, C., Luetkenhaus, K., Serafin, V., Zanucco, E., Castro, I., and Potapenko, T. (2009) MYC is a metastasis gene for non-small-cell lung cancer. PLoS One 4, e6029
42. Li, X., Liu, X., Xu, W., Zhou, P., Gao, P., Jiang, S., Lobie, P. E., and Zhu, T. (2013) c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2. J. Biol. Chem. 288, 18121-18133
43. Zhang, X. Y., DeSalle, L. M., Patel, J. H., Capobianco, A. J., Yu, D., Thomas-Tikhonenko, A., and McMahon, S. B. (2005) Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc. Natl. Acad. Sci. U.S.A. 102, 13968-13973
44. Nag, A., and Smith, R. G. (1989) Amplification, rearrangement, and elevated expression of c-Myc in the human prostatic carcinoma cell line LNCaP. Prostate 15, 115-122
45. Jenkins, R. B., Qian, J., Lieber, M. M., and Bostwick, D. G. (1997) Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 57, 524-531
46. Gurel, B., Iwata, T., Koh, C. M., Jenkins, R. B., Lan, F., Van Dang, C., Hicks, J. L., Morgan, J., Cornish, T. C., Sutcliffe, S., Isaacs, W. B., Luo, J., and De Marzo, A. M. (2008) Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod. Pathol. 21, 1156-1167
47. Manning, B. D., and Cantley, L. C. (2007) AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274
48. Engelman, J. A., Luo, J., and Cantley, L. C. (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619
49. Marte, B. M., and Downward, J. (1997) PKB/Akt: connecting phosphoinositide3-kinase to cell survival and beyond. Trends Biochem. Sci. 22, 355-358
50. Altomare, D. A., and Testa, J. R. (2005) Perturbations of the Akt signaling pathway in human cancer. Oncogene 24, 7455-7464
51. Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., and Mills, G. B. (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 988-1004
52. Ellwood-Yen, K., Graeber, T. G., Wongvipat, J., Iruela-Arispe, M. L., Zhang, J., Matusik, R., Thomas, G. V., and Sawyers, C. L. (2003) Mycdriven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223-238
53. Watson, P. A., Ellwood-Yen, K., King, J. C., Wongvipat, J., Lebeau, M. M., and Sawyers, C. L. (2005) Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res. 65, 11565-11571
54. Vita, M., and Henriksson, M. (2006) The Myc oncoprotein as a therapeutic target for human cancer. Semin. Cancer Biol. 16, 318-330
55. Evan, G. (2012) Taking a back door to target Myc. Science 335, 293-294
56. Kessler, J. D., Kahle, K. T., Sun, T., Meerbrey, K. L., Schlabach, M. R., Schmitt, E. M., Skinner, S. O., Xu, Q., Li, M. Z., Hartman, Z. C., Rao, M., Yu, P., Dominguez-Vidana, R., Liang, A. C., Solimini, N. L., Bernardi, R. J., Yu, B., Hsu, T., Golding, I., Luo, J., Osborne, C. K., Creighton, C. J., Hilsenbeck, S. G., Schiff, R., Shaw, C. A., Elledge, S. J., and Westbrook, T. F. (2012) A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335, 348-353
57. Gupta, S., Srivastava, M., Ahmad, N., Sakamoto, K., Bostwick, D. G., and Mukhtar, H. (2001) Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 91, 737-743
58. Matsuyama, M., Yoshimura, R., Mitsuhashi, M., Hase, T., Tsuchida, K., Takemoto, Y., Kawahito, Y., Sano, H., and Nakatani, T. (2004) Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int. J. Oncol. 24, 821-827
59. Werz, O. (2002) 5-Lipoxygenase: cellular biology and molecular pharmacology. Curr. Drug Targets Inflamm. Allergy 1, 23-44
60. Ghosh, J. (2008) Targeting 5-lipoxygenase for prevention and treatment of cancer. Curr. Enzyme Inhib. 4, 18-28
61. Moretti, R. M., Montagnani Marelli, M., Sala, A., Motta, M., and Limonta, P. (2004) Activation of the orphan nuclear receptor RORα counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase. Int. J. Cancer 112, 87-93
62. Yang, P., Collin, P., Madden, T., Chan, D., Sweeney-Gotsch, B., Mc-Conkey, D., and Newman, R. A. (2003) Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenase. Prostate 55, 281-291
63. Pham, H., Vang, K., and Ziboh, V. A. (2006) Dietary γ-linolenate attenuates tumor growth in a rodent model of prostatic adenocarcinoma via suppression of elevated generation of PGE(2) and 5S-HETE. Prostaglandins Leukot. Essent. Fatty Acids 74, 271-282
64. Ochoa, J. J., Farquharson, A. J., Grant, I., Moffat, L. E., Heys, S. D., and Wahle, K. W. (2004) Conjugated linoleic acids (CLAs) decrease prostate cancer cell proliferation: different molecular mechanisms for cis-9, trans-11 and trans-10, cis-12 isomers. Carcinogenesis 25, 1185-1191
65. Chen, X. S., Sheller, J. R., Johnson, E. N., and Funk, C. D. (1994) Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372, 179-182
66. Funk, C. D. (1996) The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim. Biophys. Acta 1304, 65-84